Immunocore to Spotlight ImmTAC® Platform Research at 2019 SITC Annual Conference

Analyses of tebentafusp data provide further insight into platform’s mechanism of action, potential link to clinical activity in uveal melanoma

(Oxfordshire, UK and Conshohocken, Pennsylvania and Rockville, Maryland, US, 31 October 2019) Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, will present new data on its proprietary ImmTAC® platform and from the tebentafusp clinical research programme at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland from 7-10 November.